Meet PSI at ESMO 2026!
PSI CRO is joining oncology leaders at ESMO 2026 to discuss the operational strategies sponsors need to maintain enrollment momentum, data quality, and execution predictability in global phase 2-3 oncology trials.
As oncology development shifts toward combination regimens, biomarker-driven enrollment, ADCs, T-cell engagers, and personalized immunotherapy, sponsors are under growing pressure to deliver globally integrated studies without compromising timelines or endpoint integrity. PSI has supported 20+ oncology drug approvals, and 10% of all novel oncology drugs approved by the FDA since 2000 included registrational data generated through PSI-supported studies.
Visit PSI at Booth #8027
Meet with PSI’s oncology and feasibility experts to discuss enrollment strategy, global site selection, operational planning, and technology-enabled trial delivery. Ask about SYNETIC™, PSI’s agentic AI site intelligence platform designed to identify high-performing oncology sites within seconds across a database of more than 3 million study sites globally.
Attending team members:
- Sylvia Demandewicz
Senior Director, Business Development - Michael Sommer
Senior Director, Business Development - Alex Houlbrook
Senior Director, Business Development & Team Lead - Alex Goñi
Senior Director, Business Development - Angela Cortes
Senior Medical Monitor, Medical Monitoring and Consulting - Javier Perez Altozano
Senior Medical Monitor, Medical Monitoring and Consulting
Related resources:
Blog: Practice-changing progress and decisive oncology breakthroughs
Case study: Keeping your pivotal study on track: Adaptability in an oncology trial
Webinar: Designing pivotal ADC trials that actually enroll
White paper: Redefining feasibility in oncology
